Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Study of effect modifiers of genetically predicted CETP reduction

View ORCID ProfileMarc-André Legault, Amina Barhdadi, View ORCID ProfileIsabel Gamache, Audrey Lemaçon, View ORCID ProfileLouis-Philippe Lemieux Perreault, View ORCID ProfileJean-Christophe Grenier, View ORCID ProfileMarie-Pierre Sylvestre, View ORCID ProfileJulie G. Hussin, David Rhainds, View ORCID ProfileJean-Claude Tardif, View ORCID ProfileMarie-Pierre Dubé
doi: https://doi.org/10.1101/2021.09.09.21263362
Marc-André Legault
1Montreal Heart Institute, Montreal, Canada
2Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada
3Université de Montréal, Department of biochemistry and molecular medicine, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc-André Legault
Amina Barhdadi
1Montreal Heart Institute, Montreal, Canada
2Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabel Gamache
1Montreal Heart Institute, Montreal, Canada
3Université de Montréal, Department of biochemistry and molecular medicine, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Isabel Gamache
Audrey Lemaçon
1Montreal Heart Institute, Montreal, Canada
2Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louis-Philippe Lemieux Perreault
1Montreal Heart Institute, Montreal, Canada
2Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Louis-Philippe Lemieux Perreault
Jean-Christophe Grenier
1Montreal Heart Institute, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jean-Christophe Grenier
Marie-Pierre Sylvestre
4Research Centre of the University of Montreal Hospital Centre, Montreal, Canada
5Department of Social and Preventive Medicine, Université de Montréal, Montréal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marie-Pierre Sylvestre
Julie G. Hussin
1Montreal Heart Institute, Montreal, Canada
6Université de Montréal, Department of medicine, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Julie G. Hussin
David Rhainds
1Montreal Heart Institute, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Claude Tardif
1Montreal Heart Institute, Montreal, Canada
6Université de Montréal, Department of medicine, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jean-Claude Tardif
Marie-Pierre Dubé
1Montreal Heart Institute, Montreal, Canada
2Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada
6Université de Montréal, Department of medicine, Montreal, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marie-Pierre Dubé
  • For correspondence: marie-pierre.dube@umontreal.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Genetic variants in drug targets can be used to predict the effect of drugs. Here, we extend this principle to assess how sex and body mass index may modify the effect of a genetically predicted lower CETP levels on biomarkers and cardiovascular outcomes.

We found sex and BMI to be modifiers of the association between genetically predicted lower CETP and lipid biomarkers in UK Biobank participants. Female sex and lower BMI were associated with higher HDL-cholesterol and lower LDL-cholesterol for a same genetically predicted reduction in CETP concentration. We found that sex also modulated the effect of genetically lower CETP on cholesterol efflux capacity in samples from the Montreal Heart Institute Biobank. However, these modifying effects did not extend to sex-differences in cardiovascular outcomes in our data.

Our results provide insight on the clinical effects of CETP inhibitors in the presence of effect modification based on observational genetic data. The approach can support precision medicine applications and help assess the external validity of clinical trials.

Competing Interest Statement

JCT reports grants from the Government of Quebec, Amarin, Esperion, Ionis, Servier, RegenXBio; personal fees from AstraZeneca, Sanofi, Servier; and personal fees and minor equity interest from Dalcor. In addition, JCT is author on a submitted patent Methods of treating a coronavirus infection using Colchicine pending, and a patent Early administration of low-dose colchicine after myocardial infarction pending. MPD and JCT have a patent Methods for Treating or Preventing Cardiovascular Disorders and Lowering Risk of Cardiovascular Events issued to Dalcor, no royalties received, a patent Genetic Markers for Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent issued to Dalcor, no royalties received, and a patent Methods for using low dose colchicine after myocardial infarction, assigned to the Montreal Heart Institute. MPD reports personal fees and other from Dalcor and personal fees from GlaxoSmithKline, other from AstraZeneca, Pfizer, Servier, Sanofi. JH has received speaker honoraria from Dalcor and District 3 Innovation Centre. Other authors have nothing to declare.

Funding Statement

The work was funded by the Canadian Institutes of Health Research (CIHR) grant #162307, the Health Collaboration Acceleration Fund from the Government of Quebec, and Genome Canada and Genome Quebec. The Montreal Heart Institute (MHI) Biobank is funded by the MHI Foundation. MAL holds a scholarship from Canadian Institutes of Health Research (CIHR); MPD holds the Canada Research Chair in Precision medicine data analysis. JCT holds the Canada Research Chair in Personalized Medicine and the Université de Montréal Pfizer-endowed research chair in atherosclerosis. JGH is an IVADO Professor and a Fonds de la Recherche en Santé (FRQS) Junior 1 fellow. IG receives a PhD scholarship from the MHI Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This project was approved by the institutional review board of the Montreal Heart Institute called “Comité d’éthique de la recherche et du développement des nouvelles technologies de l’Institut de Cardiologie de Montréal” under project number 2015-1856. All participants of the UK Biobank gave written consent and the UK Biobank has approval from the “North West Multi-centre Research Ethics Committee” (MREC).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All UK Biobank data is accessible to health researches following their internal approval process. The process to gain access is described here: https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access

https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted September 14, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Study of effect modifiers of genetically predicted CETP reduction
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Study of effect modifiers of genetically predicted CETP reduction
Marc-André Legault, Amina Barhdadi, Isabel Gamache, Audrey Lemaçon, Louis-Philippe Lemieux Perreault, Jean-Christophe Grenier, Marie-Pierre Sylvestre, Julie G. Hussin, David Rhainds, Jean-Claude Tardif, Marie-Pierre Dubé
medRxiv 2021.09.09.21263362; doi: https://doi.org/10.1101/2021.09.09.21263362
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Study of effect modifiers of genetically predicted CETP reduction
Marc-André Legault, Amina Barhdadi, Isabel Gamache, Audrey Lemaçon, Louis-Philippe Lemieux Perreault, Jean-Christophe Grenier, Marie-Pierre Sylvestre, Julie G. Hussin, David Rhainds, Jean-Claude Tardif, Marie-Pierre Dubé
medRxiv 2021.09.09.21263362; doi: https://doi.org/10.1101/2021.09.09.21263362

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (241)
  • Allergy and Immunology (521)
  • Anesthesia (125)
  • Cardiovascular Medicine (1425)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (292)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (585)
  • Epidemiology (10306)
  • Forensic Medicine (6)
  • Gastroenterology (528)
  • Genetic and Genomic Medicine (2636)
  • Geriatric Medicine (254)
  • Health Economics (497)
  • Health Informatics (1739)
  • Health Policy (790)
  • Health Systems and Quality Improvement (676)
  • Hematology (267)
  • HIV/AIDS (568)
  • Infectious Diseases (except HIV/AIDS) (12103)
  • Intensive Care and Critical Care Medicine (649)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (291)
  • Neurology (2466)
  • Nursing (145)
  • Nutrition (379)
  • Obstetrics and Gynecology (493)
  • Occupational and Environmental Health (568)
  • Oncology (1327)
  • Ophthalmology (403)
  • Orthopedics (147)
  • Otolaryngology (237)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (343)
  • Pediatrics (784)
  • Pharmacology and Therapeutics (330)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2405)
  • Public and Global Health (5018)
  • Radiology and Imaging (895)
  • Rehabilitation Medicine and Physical Therapy (530)
  • Respiratory Medicine (682)
  • Rheumatology (309)
  • Sexual and Reproductive Health (256)
  • Sports Medicine (246)
  • Surgery (298)
  • Toxicology (45)
  • Transplantation (141)
  • Urology (108)